-
2023-505028-74-00
5
2024-01-29
Coronary artery disease
-
2022-503114-23-00
3
2023-12-19
Breast Cancer
-
2022-502082-22-00
11
2023-09-14
prediabetes
-
2022-502703-30-00
6
2023-06-28
neuroendocrine tumours
-
2024-515293-27-00
4
2023-02-24
Malignant pleural mesothelioma, epithelioid subtype (stage I-IV)
-
2022-500311-39-00
6
2022-09-08
Patients with Crohn's disease undergoing surgery and having at least o
-
2023-507699-38-00
5
2022-08-30
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
-
2023-503267-42-00
5
2022-06-10
Patients with a histological diagnosis of mismatch- repair deficient h
-
2023-506891-28-00
5
2022-05-02
The target population of interest in this study is participants with l
-
2023-506857-40-00
5
2019-01-08
Prostate Cancer
-
2023-506146-23-00
4
2025-11-17
Non-Muscle-Invasive Urothelial Carcinoma (NMIBC) of the Bladder
-
2024-515740-23-00
5
2025-03-25
Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
-
2024-515538-34-00
10
2025-02-27
Head and Neck Squamous Cell Carcinoma
-
2024-511016-25-00
4
2025-01-15
Chronic hepatitis B infection
-
2023-504040-34-01
5
2024-11-12
Crohn’s Disease
-
2024-510908-37-00
5
2024-08-28
KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (
-
2023-508166-15-00
6
2024-04-29
Ulcerative colitis (UC), Inflammatory bowel disease type unclassified
-
2023-503231-17-00
5
2024-04-26
Unresectable Pleural Mesothelioma
-
2022-502446-27-00
5
2024-02-26
Relapsed or Refractory Myeloma
-
2022-502669-14-00
5
2023-12-18
Small cell lung cancer (SCLC)
-
2022-500802-16-00
5
2023-11-01
Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung
-
2022-501576-25-00
5
2023-07-07
Melanoma
-
2022-502145-10-00
5
2023-06-06
Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor
-
2024-511169-12-00
5
2023-03-28
Non-Small Cell Lung Cancer